Novo Nordisk has reported that it is increasing its drug development capacity by investing kr500m ($100m) in a new R&D facility in Bagsværd, Denmark.
The new pilot facility will expand the company’s ability to make active pharmaceutical ingredients (APIs) for a growing number of diabetes drugs under development.
The new 2,700m² pilot plant will be fully operational by late 2016 and will be run by CMC Supply (Chemistry, Manufacturing and Control Supply), a unit within Novo Nordisk R&D.
CMC Supply, a unit within Novo Nordisk R&D, is focused on the development, production and formulation of all new protein and peptide processes in Novo Nordisk.
CMC Supply senior vice-president Jesper Bøving said that the new purification pilot plant will significantly increase the company’s capacity for early-phase diabetes projects.
"It will create up to 35 new jobs over a two-year period, in addition to the 100 new employees CMC Supply will hire in Denmark in 2014," Bøving said.
The new plant will initially house one purification line and can be expanded to the double size to further increase the capacity.
Last month, Innate Pharma acquired full development and commercialisation rights to the anti-NKG2A antibody, a first-in-class immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
By licensing anti-NKG2A to Innate, Novo Nordisk will receive €2m in cash and 600,000 shares and also be eligible to a total of €20m in potential registration milestones and single-digit tiered royalties on future sales.
With more than 38,000 employees in 75 countries, the company markets its products in more than 180 nations.
Novo Nordisk also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Image: Novo Nordisk headquarters in Bagsværd, Denmark. Photo: courtesy of Novo Nordisk.